Dominant optic atrophy (DOA) is genetically heterogeneous and pathogenic mutations have been identified in the OPA1 and OPA3 genes, both encoding for mitochondrial proteins. We characterized clinical and laboratory features in a large OPA1-negative family with complicated DOA. Search for mitochondrial dysfunction was performed by studying muscle biopsies, fibroblasts, platelets and magnetic resonance (MR) spectroscopy. Genetic investigations included mitochondrial DNA (mtDNA) analysis, linkage analysis, copy number variation (CNV) analysis and candidate gene screening. Optic neuropathy was undistinguishable from that in OPA1-DOA and frequently associated with late-onset sensorineural hearing loss, increases of central conduction times at somato-sensory evoked potentials and various cardiac abnormalities. Serum lactic acid after exercise, platelet respiratory complex activities, adenosine triphosphate (ATP) content in fibroblasts and muscle phosphorus MR spectroscopy all failed to reveal a mitochondrial dysfunction. However, muscle biopsies and their mtDNA analysis showed increased mitochondrial biogenesis. Furthermore, patient's fibroblasts grown in the galactose medium were unable to increase ATP content compared with controls, and exhibited abnormally high rate of fusion activity. Genome-wide linkage revealed a locus on chromosome 16q21 -q22 with a maximum two-point LOD score of 8.84 for the marker D16S752 and a non-recombinant interval of ∼ 6.96 cM. Genomic screening of 45 genes in this interval including several likely candidate genes (CALB2, CYB5B, TK2, DHODH, PLEKHG4) revealed no mutation. Moreover, we excluded the presence of CNVs using array-based comparative genome hybridization. The identification of a new OPA locus (OPA8) in this pedigree demonstrates further genetic heterogeneity in DOA, and our results indicate that the pathogenesis may still involve mitochondria.
INTRODUCTION
Kjer-type dominant optic atrophy (DOA; OMIM#165500) is a progressive form of retinal ganglion cell degeneration with childhood onset and variable severity (1, 2) . Slowly progressive loss of axons depletes bilaterally the optic nerves starting from the temporal side, thus involving predominantly the small and thinly myelinated fibers of the papillomacular * To whom correspondence should be addressed. Tel: +39 0512092747; Fax: +39 0512092751; Email: valerio.carelli@unibo.it # The Author 2011. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com bundle (3) . This pattern of axonal loss leads to an insidious visual impairment with cecocentral scotoma, color vision defect and progressive optic nerve pallor. However, clinical expression may range from asymptomatic carriers to legally blind individuals with either inter-as well as intra-familial variability. In long lasting and severe cases, the optic disc becomes diffusely atrophic with pale appearance and eventually excavated.
Genetic analysis of DOA families led to the identification of three loci (OPA1, OPA4 and OPA5) on chromosome 3q28 -q29 (4), chromosome 18q12.2-q12.3 (5) and chromosome 22q (6) . Only the OPA1 gene has been identified so far (7, 8) . Screening studies in DOA families of different ethnic origin indicate that mutations in OPA1 are the most prevalent cause of DOA (9, 10) . More than 200 different mutations, including missense, nonsense, small deletion/insertions, splicing mutations and larger genomic rearrangements have already been described (see http://lbbma.univ-angers.fr). The OPA1 gene encodes a dynamin-related GTPase that is imported into mitochondria and plays a prominent role in mitochondrial fusion processes, stabilization of cristae and cytochrome c sequestration (11, 12) . Besides OPA1, it has been shown that missense mutations in the OPA3 gene on chromosome 19q13.2 -q13.3, which was originally identified as gene mutated in autosomal recessive type III 3-methylglutaconic aciduria (optic atrophy plus syndrome or Costeff optic atrophy syndrome; OMIM#258501) (13) , can also cause a dominantly inherited form of optic atrophy associated with cataract (14) . The protein encoded by the OPA3 gene also localizes to mitochondria; yet its function remains poorly characterized (15, 16) .
A subgroup of DOA families displays a more widespread phenotype including optic atrophy and sensorineural hearing loss (SNHL) (17, 18) , and more rarely also ptosis, chronic progressive external ophthalmoplegia and myopathy (19, 20) . Interestingly, the same OPA1 mutation at position c.1334G.A in exon 14 inducing the amino acid change R445H has been found in these subtypes of complex DOA (21, 22) . Recently, multiple families carrying the c.1334G.A and other missense mutations, affecting the GTPase domain, were described with a syndromic form of DOA characterized by mitochondrial myopathy with mitochondrial DNA (mtDNA) multiple deletions, and central and peripheral nervous system involvement (23, 24) . These studies revealed a novel role of the OPA1 protein in mtDNA stability and a new pathogenic mechanism leading to a syndromic DOA or 'plus' phenotype. Not surprisingly, an 'in vivo' subclinical involvement of skeletal muscle was also reported in patients carrying the 'common' OPA1 c.2708 -2711del(TTAG) frameshift mutation, as well as other pathogenic OPA1 mutations, shown by defective mitochondrial adenosine triphosphate (ATP) synthesis at phosphorus magnetic resonance spectroscopy ( 31 P-MRS) (25, 26) . Moreover, oxidative phosphorylation dysfunction was described in fibroblasts carrying different OPA1 mutations inducing haploinsufficiency and in fibroblasts carrying OPA3 mutations (27, 28) .
We now report on a large Italian family with DOA complicated by late-onset SNHL, neurophysiological evidence of subclinical central nervous system involvement and recurrent cardiac abnormalities, which does not link to any of the previously reported gene loci. We characterized the clinical, biochemical, brain magnetic resonance imaging (MRI) and skeletal muscle 31 P-MRS features of this large pedigree. Genome-wide linkage analysis identified a new locus (OPA8) on chromosome 16q21 -q22 segregating with the disease in this family, and we excluded mutations in the coding sequences of 45 top-ranked candidate genes including CALB2, CYB5B, TK2, DHODH and PLEKHG4 as well as the presence of copy number variations (CNVs) within the OPA8 critical interval.
RESULTS

Ascertainment of the family and clinical
and ophthalmologic studies Figure 1 shows the most comprehensive reconstruction of the Italian pedigree with complicated DOA (cDOA) investigated in the present study. The family spans over eight generations and is located mostly in the Italian region of Emilia-Romagna. Based on direct examination or by clinical history, we identified 53 affected subjects over a total of 263 individuals, considering the optic neuropathy as the core clinical manifestation. The pattern of inheritance was clearly dominant with only two instances of apparent lack of penetrance.
A uniform protocol of clinical investigations was applied to a set of five affected individuals and the results are summarized in Table 1 . The optic atrophy was invariably present in all individuals, who also showed variable impairments in pattern visual evoked potentials (P-VEPs). Late onset SNHL, selective for high frequencies, was observed at audiometry in two cases and alteration of the brainstem auditory evoked potentials (BAEPs) was found in three subjects, the oldest of the five investigated. Furthermore, all individuals showed normal findings along the peripheral sensory and motor fibers, but variably increased central conduction time of somato-sensory evoked potentials (SSEPs), suggesting some involvement of the dorsal columns. We also noted that all investigated individuals presented with variable degrees of mitral valve insufficiency or prolapse, and some abnormalities in cardiac repolarization in two of five subjects ( Table 1 ). The investigation of muscle biopsies did not reveal clear-cut features suggestive of mitochondrial pathology (Table 1) . However, all biopsies showed variable degrees of subsarcolemmal accumulations of mitochondria, as documented by the succinate dehydrogenase (SDH) and cytochrome c oxidase (COX)/SDH stains and by electron microscopy ( Fig. 2A -F) , and occasional COXdepleted or -negative fibers were found only in the older subjects ( Fig. 2C and D) . The serum lactic acid after muscle exercise was normal in all cases except individual VI-17 who had a mild elevation (Table 1) .
Besides the above in-depth clinical investigations on the set of five affected individuals, a further group of 11 patients underwent a comprehensive ophthalmologic examination and the results are reported in Supplementary Material, Table S1 . Overall, all 16 patients showed optic atrophy with central scotoma and reduced visual acuity ranging from 0.9 to 0.05 (Supplementary Material, Fig. S1A ). The optical coherence tomography (OCT) evaluation of the retinal nerve fiber layer (RNFL) thickness consistently showed a thinning in the temporal and inferior quadrants corresponding to the fibers of the papillomacular bundle (Supplementary Material, Table S1 ), all others also suffered a generalized reduction in RNFL thickness on the other quadrants 
mtDNA content and integrity
To assess possible mtDNA abnormalities in our cDOA family, we investigated for qualitative and quantitative defects of mtDNA in muscle biopsies. The occurrence of mtDNA multiple deletions was assessed by long-range polymerase chain reaction (PCR), but failed to show any significant accumulation. Low amounts of mtDNA deletions were detected in the older subjects, compatible with their age-related occurrence (data not shown). We also assessed the mtDNA copy number by realtime PCR, which revealed a tendency towards increased mtDNA content in the five cDOA subjects. This increase was significant in two subjects compared with age-matched control muscle samples (n ¼ 17, Fig. 2G ). Pooling the cDOA subjects, they showed a significantly higher mtDNA content compared with the age-matched control group (Fig. 2H ). This result is consistent with an increased mitochondrial biogenesis as detected by histoenzymatic staining with COX/SDH and electron microscopy ( Fig. 2A-F) . A similar assessment of mtDNA copy number was also carried out on DNA extracted from venous blood, comparing 16 cDOA patients with 16 agematched controls (spouses), showing again a tendency to increased mtDNA content in cDOA, but without reaching statistical significance (Fig. 2I ).
Biochemical studies
Previous reports documented a defective oxidative phosphorylation in DOA patients with OPA1 and OPA3 mutations (25 -28) . We failed to show defects in enzymatic activities of respiratory complexes on the platelet-enriched fraction from our cDOA patients compared with controls. Furthermore, ATP content determined in fibroblasts from cDOA patients, Fibroblasts incubation in Dulbecco's modified Eagle medium (DMEM) galactose, switching cell metabolism from glycolytic to oxidative (29) , induced a remarkable increase in the ATP levels of control fibroblasts compared with the glucose medium. In contrast, cDOA fibroblasts failed to significantly increase their ATP content under the same conditions and incubation times, behaving in the same way as the OPA1 fibroblasts (Fig. 3) .
Overall, these results clearly indicate that the energetic competence of our cDOA patients, measured with different biochemical assays in two different tissues, is essentially unaffected. However, under the stressful condition of forced oxidative phosphorylation fibroblasts derived from cDOA patients displayed a reduced capacity to adjust their ATP levels, which parallels our previous results in OPA1, being slightly more severe (Fig. 3 ) (27) .
Mitochondrial network dynamics
We have previously shown that fibroblasts with OPA1 mutations leading to haploinsufficiency present with altered mitochondrial morphology and fusion rates when grown in the galactose medium (27) . Mitochondrial morphology, after loading control and cDOA fibroblasts with Mitotracker Red, showed a typical long and interconnected network both in glucose and galactose media (see Supplementary Results and Supplementary Material, Fig. S3 ) (27) . A quantitative mitochondrial fusion assay, which measures the spread rate of matrix-targeted photoactivable green fluorescent protein (mt-PAGFP) (30) , was then used to evaluate whether this process is altered in cDOA fibroblasts. Small regions of cells transfected with mt-PAGFP were photoactivated and the decrease in fluorescence over time was determined by confocal microscopy. Representative images of one control and one cDOA fibroblast in the glucose and in galactose media at 0, 30 and 60 min after photoactivation are shown in Figure 4A . In the glucose medium, the decrease in fluorescence within the activated regions of cDOA fibroblasts was slightly faster than in controls, without reaching statistical significance (Fig. 4B) . In DMEM galactose, cDOA fibroblasts showed a stronger decline in mt-PAGFP fluorescence than in glucose at 60 min after photoactivation, indicating a faster rate of mitochondrial fusion under these conditions (Fig. 4C) . These results are similar to those previously obtained with OPA1 mutant fibroblasts in the glucose medium, whereas in the DMEM-galactose medium the OPA1 mutant fibroblasts displayed an increased fusion rate only in the subset of cells where the interconnected tubular network was maintained (27) .
MR studies: imaging and spectroscopy
Brain MRI was normal in seven out of eight cDOA patients studied. Patient V-83, aged 64 years, presented, on T2-weighted images, multiple hyperintense foci in the periventricular, semioval centra and subcortical white matter (data not shown).
The evaluation of skeletal muscle energy metabolism in five cDOA patients through 31 P-MRS did not show any abnormality at rest or during exercise (Table 1) . Mean 1/phosophorylation potential at rest was similar in cDOA patients (12 + 2 mM × 10 6 ) and controls (11 + 3 mM × 10 6 ; P ¼ 0.6) as well as the maximum rate of mitochondrial ATP production (45 + 5 versus 47 + 7 mM/min; P ¼ 0.6).
Molecular genetic analysis
Two male subjects originally seen in the clinic (individuals VI-17 and VI-47) were initially investigated as possible Leber's hereditary optic neuropathy (LHON) patients because of apparent maternal transmission of visual loss. The three common mtDNA mutations associated with LHON at positions 11778/ND4, 3460/ND1 and 14484/ND6 were excluded. The pattern of disease segregation was subsequently recognized as dominant with multiple instances of paternal transmission and the original families of the two subjects were linked within the very large pedigree currently reconstructed as shown in Figure 1 . Given the dominant transmission and the clinical characteristics of the optic neuropathy with early onset and slowly progressive course, a diagnosis of Kjer-type DOA was suspected and the OPA1 gene investigated.
Screening of the OPA1 gene in subject VI-17 by complete sequencing of the coding exons and flanking intron sequences amplified from genomic DNA and the OPA1 cDNA obtained from whole blood RNA revealed no pathogenic mutation. Exclusion of OPA1 was further substantiated by nonconcordant segregation of closely linked microsatellite markers in a subset of family members. Further segregation analysis with markers covering the previously described OPA4 disease locus on chromosome 18 and markers in close proximity to MFN2 (chromosome 1p36), MFN1 and PARL (chromosome 3q26 and 3q27), candidate genes that are involved in mitochondrial membrane fusion/fission processes or OPA1 protein processing, respectively, also turned out to be inconsistent with linkage (Z max ≤ 22 at Q ¼ 0.02).
Therefore, we performed a genome-wide linkage scan with microsatellite markers on a subset of family members. For this analysis, we included only clinically well-assessed affected family members from two informative family branches to avoid linkage failure due to incomplete penetrance as described in DOA families (31) . A peak LOD score of Z ¼ 2.9 was obtained for the marker D16S515 in comparison with the second highest LOD score of Z ¼ 1.7 with the marker D12S1723. The chromosome 16 locus surpassed the threshold of Z ¼ 3.0 for significant linkage with the inclusion of additional family members into the analysis. Of all further genotyped markers in that region, significant LOD scores equal or above 3.0 were calculated for D16S503, D16S3050, D16S397, D16S3067, D16S752, D16S3066, D16S3018 and D16S515 with a maximum LOD score of Z ¼ 8.84 at Q ¼ 0.0 for D16S752 (Supplementary Material, Table S2 ). Haplotype reconstruction revealed a non-recombinant interval of 6.96 cM flanked by markers D16S3050 and D16S3018 as defined by meiotic breakpoints in three affected family 
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Human (Fig. 5) . The current annotation of the human genome sequence (build 36.3) lists 177 known or hypothetical genes in this critical interval but does not contain any locus or disease gene known to cause optic neuropathy. However, several studies reported a locus for autosomal dominant spinocerebellar ataxia that is linked to markers within the interval defined in our family (32) . Recently, Ishikawa et al. (33) reported that a mutation in the 5 ′ UTR of PLEKHG4 may be responsible for autosomal dominant cerebellar ataxia type III (ADCA type III) in Japanese families.
Since hearing loss is reported in a large proportion of ADCA type III patients and PLEKHG4 is expressed in the cochlea, we considered PLEKHG4 as a candidate gene in our Italian cDOA family. However, no mutation was detected in the coding sequence, the exon/intron boundaries or the 5 ′ UTR. Similarly, no mutation was detected in the coding exons of CALB2, CYB5B, TK2 and DHODH, other primary candidates based on retinal expression and/or mitochondrial function. For the selection of further candidate genes, we prioritized all genes in the interval based on the following criteria: (i) retinal expression, (ii) expression in the cochlea, (iii) mitochondrial function, (iv) association with apoptosis and/or neurodegenerative disease, and (v) in silico expression correlation analysis with OPA1 as query. From that list, we choose the top 45 genes for mutation screening by DNA sequencing of all coding exons and flanking intron/UTR sequences (in total 322 exons) in two affected members of the family and four other non-OPA1 DOA subjects. Supplementary Material, Table S3 lists all investigated genes and the screening results. In total, we found 37 sequence variations; 31 thereof represent known polymorphisms. Of the remaining six unknown sequence variations, four did not segregate with the disease phenotype in the family, i.e. were located on the non-mutant chromosome. One of the segregating sequence variants was a heterozygous G-to-C transversion in intron 7 (at nucleotide position c.769+10G.C) of the VPS4A gene, which encodes an ATPase involved in intracellular membrane trafficking (34) . This sequence variant could not be found in a screen of 169 control subjects (n ¼ 338 chromosomes). We therefore performed cDNA analysis of the VPS4A gene using RNA of a lymphoblastoid cell line established from patient (VII:12). Amplification of a cDNA fragment with primers located in exon 5 and exon 9 yielded only one fragment of the expected size in patients as well as in controls (data not shown), ruling out the possibility that the sequence variant does affect transcript processing. The second disease-segregating variant was identified in the PHLPPL gene, which has a high probability of being localized in mitochondria (probability of 87.9% as predicted by MitoProt II) and which was ranked top in the in silico correlation analysis with OPA1 (Supplementary Material, Table S4 ). In this gene, we found a heterozygous c.2756G.A transition that results in an amino acid exchange (p.S919N) in a reasonably conserved region of the protein. However, this variant was classified as benign by PolyPhen analysis (http://genetics.bwh.harvard.edu/pph/) and was also found in a heterozygous state in seven normal healthy controls in a screen of 190 healthy control subjects (n ¼ 380 chromosomes). It has become increasingly evident that CNVs play an important role in hereditary disease. Since qualitative PCR-based methods does not account for larger structural rearrangements and CNVs, we performed comparative genome hybridization (CGH) for two affected subjects of our family using a ready designed 385k Nimblegen chromosome 16 CGH array. This CGH array analysis did not show any CNV within the OPA8 interval and thus ruled out the presence of larger deletions or insertions as a cause for the disease in this family (Supplementary Material, Fig. S4 ). Furthermore, we applied STS content mapping with DNA of a monochromosomal mouse-human cell hybrid carrying the OPA8-linked disease chromosome. All coding exons of the 19 investigated genes (listed in Supplementary Material, Table S3 , last column), including the principal candidate genes PLEKHG4, CALB2, CYB5B, TK2 and DHODH, could be readily amplified and thus further excluded heterozygous microdeletions in these genes (data not shown).
DISCUSSION
In this study, we report the comprehensive clinical and biochemical investigation of a large Italian family with DOA, neurophysiological evidence of spinal dorsal column involvement, cardiac involvement with mitral valve insufficiency or prolapse and repolarization defect and late onset SNHL selective for high frequencies. This complicated form of DOA was not associated with any mutation in the coding regions of OPA1, nor linked to this or other candidate genes and known DOA loci. Genome-wide microsatellite marker analysis led to significant linkage with markers on chromosome 16q22, defining a new locus for DOA assigned as OPA8 by the Human Genome Nomenclature Committee.
The clinical phenotype in this family was characterized by the consistent presence of optic neuropathy though variable in expression, which showed all the hallmark features of DOA associated with OPA1 mutations. The natural history of visual loss was variable, ranging from very mild to severe cases, most of them with disease onset clearly recognized before 10 years of age. Patients showed preferential and precocious involvement of the papillomacular bundle with temporal atrophy, which eventually extended to the entire optic disc. This is a typical hallmark feature of mitochondrial optic neuropathies (3) . Consequently, all patients had central visual loss with cecocentral scotomas. The typical pattern of papillomacular involvement was further substantiated by the OCT investigation (35) . In fact, reduction in RNFL thickness was, in early stages, restricted to the temporal and inferior quadrants and followed, in an age-related fashion, by a diffuse loss in all other quadrants.
Optic neuropathy, in a subset of patients, was associated with variable degrees of age-dependent SNHL, closely resembling early stages of presbiacusia. Complains of hearing loss were very variable among the family members and further investigations are needed to better characterize the acoustic nerve involvement. Furthermore, we also uncovered neurophysiological evidence of subclinical central nervous system involvement, as shown by the increased central conduction times at SSEPs. One patient presented some white matter abnormalities of possible vascular origin. Finally, we noted the constant occurrence of mitral valve insufficiency and/or prolapse. Considering the fact that the five subjects investigated were from distant family branches, the cardiac involvement may represent another clinical manifestation of this disease, which needs a systematic investigation within the family.
The typical ophthalmologic features of mitochondrial optic neuropathy prompted us to investigate the hypothesis of a mitochondrial dysfunction in this family. An extensive set of exams, including evaluation of serum lactic acid after standardized exercise, assessment of platelet respiratory complex activities and skeletal muscle 31 P-MR spectroscopy, failed to recognize a clear dysfunction of mitochondrial respiratory chain that, in turn, was detected in OPA1-associated DOA patients (25, 26) . However, the histoenzymatic staining on muscle biopsies revealed a variable subsarcolemmal increase in mitochondrial activities (SDH and COX), indicating a mitochondrial proliferation, as also documented at electron microscopy. Furthermore, the analysis of mtDNA copy number in muscle and blood also confirmed variable degrees of increased mitochondrial biogenesis compared with age-matched controls, having excluded that both patients and controls were under increased level of muscle exercise. This feature is a classic compensatory mechanism seen in mitochondrial disorders (36) . We also occasionally noted some muscle fibers with partial or complete depletion of COX activity, but the mtDNA analysis showed low levels of mtDNA deletions, compatible with the age of the patients investigated.
To better explore the mitochondrial function, we established fibroblast cell lines from the five patients fully investigated and performed the same set of biochemical and morphological experiments, which previously allowed us to characterize the cellular phenotype of OPA1 mutations (27) . In analogy to our results with OPA1 mutant fibroblasts, we also found that the cDOA fibroblasts presented a reduced energetic competence when grown in DMEM galactose, despite normal ATP production in the glucose medium. However, in contrast to OPA1 mutant fibroblasts, the cDOA cells did not undergo mitochondrial network fragmentation in the galactose medium. When the mitochondrial fusion activity was measured, we also observed an increased fusion rate of cDOA fibroblasts in the galactose medium when compared with controls. This latter feature was previously described in the subset of OPA1 fibroblasts able to maintain a tubular and interconnected mitochondrial network, whereas in the remaining cells exhibiting hyperfragmented mitochondria the fusion activity was virtually abolished (27) .
All considered, the current results support the possibility that the clinical phenotype described in this Italian pedigree may depend on a direct or indirect mitochondrial dysfunction. The major indications are the classic pattern of mitochondrial optic neuropathy, the increased mitochondrial biogenesis in skeletal muscle, the limited bioenergetic competence of fibroblasts in the galactose medium as well as the abnormalities in their fusion activity. A protein directly or indirectly involved in regulation of mitochondrial network dynamics seems a good candidate.
Our genetic analyses demonstrated a linkage on chromosome 16q22, defining a new locus (assigned OPA8) for DOA. OPA8 represents the fifth locus for DOA including the two known genes, OPA1 and OPA3, and the two loci OPA4 and OPA5 for which the genes have not yet been identified. Refined mapping narrowed the OPA8 locus to an interval of 6.96 cM flanked by markers D16S3050 and D16S3018. These borders are defined by meiotic recombinations reconstructed in affected subjects. There are currently 177 genes listed in the OPA8 interval. We selected and screened the complete coding sequence of 45 top-ranked candidate genes including genes with known mitochondrial function (TK2, CYB5B and DHODH), CALB2, a gene highly enriched in retinal ganglion cells and PLEKHG4, which was reported to be implicated in ADCA type III (33) . However, no putatively pathogenic mutation was detected in these genes. Moreover, we ruled out the presence of CNVs as a cause of the disease in this family.
Our analysis does not exclude the presence of pathogenic mutations in introns or in non-coding regulatory sequences of the analyzed genes. Therefore, besides the investigation of further genes in the interval, cDNA analysis is warranted to exclude those genes with confidence.
The mapping of the OPA8 locus may hopefully lead to the identification of further OPA8-linked families that eventually lead to the refinement of the locus. Moreover, additional mutant alleles will increase the chance to pinpoint the involved gene through conventional screening methods or high throughput sequencing technologies.
MATERIALS AND METHODS
Clinical investigations
Clinical history, neurological examination, neurophysiological investigations including P-VEPs, electroretinogram, BAEPs, motor evoked potentials, SSEPs, electromyography and electroneurography, electrocardiogram, serum lactic acid after muscle exercise and muscle biopsy were performed in a set of five affected individuals from distantly related branches of the family (V-83, VI-8, VI-17, VI-75, VII-13 in Fig. 1) .
A larger group of 16 patients (in addition to the previous five, also VI-5, VI-12, VI-14, VI-25, VI-29, VI-52, VI-112, VII-6, VII-12, VII-49, VIII-1 in Fig. 1 ) underwent an extensive ophthalmologic investigation, including best-corrected visual acuity, slit-lamp biomicroscopy, intraocular pressure measurement, indirect ophthalmoscopy, fundus picture, visual field testing by Humphrey Field Analyzer (ZeissHumphrey Systems, Dublin, CA, USA) and RNFL analysis by OCT (StratusOCT, software version 4.0.1; Carl Zeiss Meditec, Inc, Dublin, CA, USA). For the latter investigation, we applied the RNFL Thickness 3.4 protocol, as previously reported (35) .
Cells and culture conditions
Skin fibroblasts were obtained, following informed consent, from five healthy donors and the five affected individuals extensively investigated in this study. Fibroblasts were grown in DMEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine and antibiotics. For the experiments, fibroblasts were grown in DMEM or in glucose-free DMEM containing 5 mM galactose and 5 mM pyruvate (DMEM galactose).
Biochemical studies
Respiratory complex activities. The activities of respiratory complexes I, II plus III, III and IV were evaluated in homogenates of the platelet-enriched fraction freshly prepared from 100 ml of venous blood as previously detailed (37) . The enzymatic activities of all respiratory complexes were normalized for citrate synthase activity (38) , to correct for variations in mitochondrial mass. For these investigations, a control group of 23 normal individuals was used.
ATP measurements. ATP was measured in fibroblasts by using the luciferin/luciferase assay as previously detailed (39) . ATP and ATP monitoring kit were purchased from Sigma (Milan, Italy).
Mitochondrial morphology and quantification of mitochondrial fusion
Fibroblasts were seeded onto 36 mm diameter dishes and grown for 24 h in DMEM or DMEM galactose. (27) .
To quantify mitochondrial fusion, fibroblasts seeded on glass cover slips were transfected with 1 mg of mitochondrial mt-PAGFP (30) and incubated in DMEM or DMEM galactose for 24 h. Images were captured with an LSM 510 confocal microscope (Carl Zeiss MicroImaging, Inc.) using a 63X1.4NA apochromat objective. The excitation and photoactivation wavelengths for mt-PAGFP were 488 and 413 nm, respectively. Regions of interest were selected and series of z-sections from the top to the cell bottom with intervals between the sections set to 0.5-0.75 mm were irradiated with 413 nm light. Images were captured immediately after photoactivation (0 min) and after 30 and 60 min. Mitochondrial fusion was calculated by obtaining the ratio between the number of pixels in the fluorescent area and the total cell number of pixels using the Volocity program. The data were exported to Microsoft Excel and converted into graphs.
MR studies
Brain magnetic resonance (MR) imaging and skeletal muscle spectroscopy studies were carried out in a 1.5 Tesla clinical whole body magnet (General Electric Medical Systems, Milwaukee, WI, USA). Conventional brain MR, which included spin-echo T1-and T2-weighted, fluid-attenuated inversion recovery and diffusion-weighted sequences, was performed in eight cases (V-83, VI-5, VI-17, VI-75, VII-8, VII-10, VII-12, VII-13 in Fig. 1 ). 31 P-MRS evaluation of skeletal muscle was performed on the right calf muscle in the five patients extensively investigated (V-83, VI-8, VI-17, VI-75, VII-13 in Fig. 1 ). Spectra were acquired at rest, during an aerobic incremental exercise of plantar flexion and the following recovery, as previously 
Genetic studies
We collected venous blood samples from 101 individuals of the family after having obtained informed consent and approval by the local board for genetic investigations. Total DNA was extracted from venous blood and muscle biopsy samples by standard lysis and phenol/chlorophorm extraction. For total blood RNA isolation, venous blood samples were collected in PAXgene Blood RNA tubes (Qiagen, Hilden, Germany) and RNA extracted following the manufacturer's instructions.
Analysis of mtDNA. To screen for the presence of mtDNA deletions and for quantification of the mtDNA/nuclear DNA ratio, we performed long-range PCR and quantitative real-time PCR, respectively, as previously described (23) . The quantification data are presented as means of at least three independent measurements.
Analysis of the OPA1 gene. The coding exons plus flanking introns of the OPA1 gene were amplified from genomic DNA as previously described (40), purified by ExoSAP (Pharmacia, Freiburg, Germany) treatment and sequenced applying BigDye Terminator chemistry (Applied Biosystems, Darmstadt, Germany). Sequencing products were separated on an ABI 3100 DNA sequencer (Applied Biosystems) and analyzed for mutations by manual inspection and computer-aided sequence alignments (SeqMan program, DNAStar, Madison, WI, USA). Total blood RNA was reverse transcribed into single-stranded cDNA with the SuperScript II First-Strand Synthesis Kit (Invitrogen GmbH, Karlsruhe, Germany) using gene-specific primers, as previously described (41) . The coding region of the OPA1 cDNA was amplified as four overlapping segments and directly sequenced, as described previously (41) .
Marker segregation analysis. Microsatellite markers linked to the OPA1 locus (D3S1601, D3S3590, D3S3642, D3S2305, D3S2748), the OPA4 locus (D18S1102, D18S1145, D18S1143, D18S474) and the candidate gene loci MFN1, PARL (D3S1754, D3S3669, D3S3609, D3S3592) and MFN2 (D1S2667, D1S228, D1S507) were genotyped by slab-gel separation and sizing of fluorescence-labeled PCR products on an ABI 377 DNA Sequencer. Marker allele and haplotype segregation was assessed manually.
Whole genome scan genotyping and linkage analysis. A genome-wide linkage scan was done applying the ABI PRISM Linkage Mapping Set version 2 that includes 362 microsatellite markers with an average distance of 10 cM. Amplification products were separated on an ABI 377 DNA sequencer and genotypes called using Genescan and Genotyper software (Applied Biosystems). The whole genome scan was done for a subset of clinically well-documented affected family members and spouses. Two-point parametric linkage calculations were done using MLINK and Superlink through the GLUE (http://www.hgmp.mrc.ac.uk/) or Superlink-online (http://bioinfo.cs.technion.ac.il/superlink-online/) web interface. We assumed an autosomal dominant mode of inheritance with a disease allele frequency of 0.0001 and full penetrance. Additional microsatellite markers chosen from available genetic and physical maps were genotyped and used for fine mapping and manual or computer-assisted haplotype reconstruction (Cyrillic 2.1, Cherwell Scientific, Reading, UK).
Screening of chromosome 16 candidate genes. A list of genes and gene predictions localizing to the OPA8 interval were retrieved from annotated human genome assemblies at NCBI and Ensembl. The data on gene expression in the retina, eye and/or cochlea, on the function and cellular localization of gene products, were compiled from public databases (e.g. Unigene, The DFCI Homo sapiens Gene Index, MITOP, Entrez Gene, VEGA, Gene Cards) and original literature.
For in silico expression correlation analysis, we retrieved from GNFSymatlas (http://symatlas.gnf.org/SymAtlas/) the available gene expression data of all genes that mapped to the OPA8 interval and the two OPA1 probes 212214_at and 212213_x_at from 46 different human tissue samples. The correlation coefficient r xy was calculated as described previously (42) . Genes were sorted descending to their r xy values and accepted as significant if r xy ≥ 0.8.
PCR primer pairs for the amplification of candidate gene exons were either designed individually using the primer 3 web interface (http://frodo.wi.mit.edu) or in batch mode using ExonPrimer (http://ihg2.helmholtz-muenchen.de). Primer sequences and PCR conditions are available upon request. PCR products were purified by ExoSAP treatment (USB, Staufen, Germany) and subsequently sequenced applying BigDye Terminator Chemistry 1.1 (Applied Biosystems, Foster City, USA). Sequencing products were precipitated with 1.25 vol 2-Propanol, washed with 80% ethanol and dissolved in water. Products were separated on an ABI 3100 DNA sequencer and analyzed for mutations by manual inspection and computer-aided sequence alignments (SeqMan program, DNAStar). For cDNA analysis of VPS4A, lymphoblastoid RNA was reverse transcribed using the Super Script III First-Strand Synthesis System for RT -PCR (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers. Single-stranded cDNA was subsequently amplified applying oligonucleotides located in exon 5 (L: 5 ′ -ACA TAC GGT GGA ACG ACG TG-3 ′ ) and in exon 9 (R: 5 ′ -TTG AAG TGT GTG GCC GAC T-3 ′ ). Monochromosomal cell hybrid. A mouse human monochromosomal hybrid cell line retaining the OPA8-linked disease chromosome 16 was established from a lymphoblastoid cell line of subject VII:12 using conversion technology (43) . The hybrid cell line was grown in HAT selection medium and its monochromosomal character for chromosome 16 was verified by microsatellite marker analysis.
